FindTrial
Sign In

Evusheld

DRUG8 trials

Sponsors

Ghady Haidar, Sunnybrook Health Sciences Centre, AstraZeneca, Fondazione IRCCS Policlinico San Matteo di Pavia

Conditions

COVID-19COVID-19; SARS-CoV-2; 2019 Novel Coronavirus DiseaseChronic Lymphocytic LeukemiaImmuno-DeficiencySARS-CoV-2SARS-CoV-2 Omicron VariantsSARS-CoV-2, COVID-19

Phase 2

Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL
WithdrawnNCT05465876
Sunnybrook Health Sciences CentreChronic Lymphocytic Leukemia, COVID-19
Start: 2023-10-31End: 2025-10-31Updated: 2024-04-04

Unknown Phase

PREP (Pre-Exposure Prophylaxis) of COVID-19
CompletedNCT05461378
Ghady HaidarCOVID-19, Immuno-Deficiency
Start: 2022-07-26End: 2024-01-29Updated: 2024-07-15
eVusheld Assessment reaL wORld Effectiveness in DoD Health System
CompletedNCT05569408
AstraZenecaCOVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
Start: 2023-08-10End: 2023-12-22Updated: 2024-09-19
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
CompletedNCT05663957
AstraZenecaSARS-CoV-2, COVID-19
Start: 2023-01-04End: 2023-09-01Updated: 2024-09-03
eVusheld Assessment reaL wORld Effectiveness at UPMC
CompletedNCT05667116
AstraZenecaSARS-CoV-2, COVID-19
Start: 2023-01-09End: 2023-07-24Updated: 2024-11-12
eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
CompletedNCT05712096
AstraZenecaCOVID-19, SARS-CoV-2
Start: 2023-03-09End: 2023-05-30Updated: 2025-01-21
An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan
CompletedNCT06156982
AstraZenecaCOVID-19
Start: 2023-12-06End: 2024-01-09Updated: 2024-06-26
REAl LIfe" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients
CompletedNCT07473986
Fondazione IRCCS Policlinico San Matteo di PaviaSARS-CoV-2 Omicron Variants
Start: 2022-07-08End: 2024-12-31Updated: 2026-03-16